Radiation therapy for ductal carcinoma in situ: A decision analysis

Por Punglia, Rinaa S., Burstein, Harold J., Weeks, Jane C.
Publicado em 2011

Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer

Por Mayer, Erica L, Carey, Lisa A, Burstein, Harold J
Publicado em 2007

Peek Before You Treat? Is It a Fantasy or Reality?

Por Ajani, Jaffer A., Mangu, Pamela B., Burstein, Harold J.
Publicado em 2011

Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

Por Punglia, Rinaa S., Burstein, Harold J., Winer, Eric P., Weeks, Jane C.
Publicado em 2008

American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Por Burstein, Harold J., Griggs, Jennifer J., Prestrud, Ann A., Temin, Sarah
Publicado em 2010

Cancer-Related Direct-to-Consumer Advertising: Awareness, Perceptions, and Reported Impact Among Patients Undergoing Active Cancer Treatment

Por Abel, Gregory A., Burstein, Harold J., Hevelone, Nathanael D., Weeks, Jane C.
Publicado no J Clin Oncol (2009)

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era

Por Olson, Erin M., Najita, Julie S., Sohl, Jessica, Arnaout, Amal, Burstein, Harold J., Winer, Eric P., Lin, Nancy U.
Publicado em 2013

Past, Present, and Future Challenges in Breast Cancer Treatment

Por Sledge, George W., Mamounas, Eleftherios P., Hortobagyi, Gabriel N., Burstein, Harold J., Goodwin, Pamela J., Wolff, Antonio C.
Publicado no J Clin Oncol (2014)

CONTRARY EFFECTS OF THE RTK INHIBITOR VANDETANIB ON CONSTITUTIVE AND FLOW-STIMULATED NITRIC OXIDE ELABORATION IN HUMANS

Por Mayer, Erica L., Dallabrida, Susan M., Rupnick, Maria A., Redline, Whitney M., Hannagan, Keri, Ismail, Nesreen S., Burstein, Harold J., Beckman, Joshua A.
Publicado no Hypertension (2011)

Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase...

Por Burstein, Harold J., Cirrincione, Constance T., Barry, William T., Chew, Helen K., Tolaney, Sara M., Lake, Diana E., Ma, Cynthia, Blackwell, Kimberly L., Winer, Eric P., Hudis, Clifford A.
Publicado no J Clin Oncol (2014)

Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based The...

Por Vaz-Luis, Ines, Seah, Davinia, Olson, Erin M., Wagle, Nikhil, Metzger-Filho, Otto, Sohl, Jessica, Litsas, Georgia, Burstein, Harold J., Krop, Ian E., Winer, Eric P., Lin, Nancy U.
Publicado em 2013

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Por Golshan, Mehra, Cirrincione, Constance T., Sikov, William M., Carey, Lisa A., Berry, Donald A., Overmoyer, Beth, Henry, Nora L., Somlo, George, Port, Elisa, Burstein, Harold J., Hudis, Clifford, Winer, Eric, Ollila, David W.
Publicado no Breast Cancer Res Treat (2016)

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Por Burstein, Harold J., Temin, Sarah, Anderson, Holly, Buchholz, Thomas A., Davidson, Nancy E., Gelmon, Karen E., Giordano, Sharon H., Hudis, Clifford A., Rowden, Diana, Solky, Alexander J., Stearns, Vered, Winer, Eric P., Griggs, Jennifer J.
Publicado no J Clin Oncol (2014)

Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study

Por Vaz-Luis, Ines, Ottesen, Rebecca A., Hughes, Melissa E., Mamet, Rizvan, Burstein, Harold J., Edge, Stephen B., Gonzalez-Angulo, Ana M., Moy, Beverly, Rugo, Hope S., Theriault, Richard L., Weeks, Jane C., Winer, Eric P., Lin, Nancy U.
Publicado em 2014

Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Allia...

Por Shulman, Lawrence N., Berry, Donald A., Cirrincione, Constance T., Becker, Heather P., Perez, Edith A., O'Regan, Ruth, Martino, Silvana, Shapiro, Charles L., Schneider, Charles J., Kimmick, Gretchen, Burstein, Harold J., Norton, Larry, Muss, Hyman, Hudis, Clifford A., Winer, Eric P.
Publicado em 2014

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Por Tolaney, Sara M., Barry, William T., Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth A., Partridge, Ann H., Guo, Hao, Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., Winer, Eric P.
Publicado no N Engl J Med (2015)

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Por Lin, Nancy U., Carey, Lisa A., Liu, Minetta C., Younger, Jerry, Come, Steven E., Ewend, Matthew, Harris, Gordon J., Bullitt, Elizabeth, Van den Abbeele, Annick D., Henson, John W., Li, Xiaochun, Gelman, Rebecca, Burstein, Harold J., Kasparian, Elizabeth, Kirsch, David G., Crawford, Ann, Hochberg, Fred, Winer, Eric P.
Publicado no J Clin Oncol (2008)

Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trial...

Por Bernhard, Jürg, Luo, Weixiu, Ribi, Karin, Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Walley, Barbara A.
Publicado no Lancet Oncol (2015)

Chemotherapy-Related Amenorrhea after Adjuvant Paclitaxel-Trastuzumab (APT Trial)

Por Ruddy, Kathryn J., Guo, Hao, Barry, William, Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Matthew J., Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth A., Hudis, Clifford, Krop, Ian E., Burstein, Harold J., Winer, Eric P., Partridge, Ann H., Tolaney, Sara M.
Publicado no Breast Cancer Res Treat (2015)

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian...

Por Ribi, Karin, Luo, Weixiu, Bernhard, Jürg, Francis, Prudence A., Burstein, Harold J., Ciruelos, Eva, Bellet, Meritxell, Pavesi, Lorenzo, Lluch, Ana, Visini, Marilena, Parmar, Vani, Tondini, Carlo, Kerbrat, Pierre, Perelló, Antonia, Neven, Patrick, Torres, Roberto, Lombardi, Davide, Puglisi, Fabio, Karlsson, Per, Ruhstaller, Thomas, Colleoni, Marco, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Regan, Meredith M., Fleming, Gini F.
Publicado no J Clin Oncol (2016)